Hemodialysis Unit, Department of Internal Medicine and Clinical Sciences, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
Auto-generated profile, based on publicly available information
Laura Zeppilli
Hemodialysis Unit, Department of Internal Medicine and Clinical Sciences, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
Aims: To evaluate the efficacy and safety of a commercially available phosphate-containing solution for continuous renal replacement therapy (CRRT) in preventing CRRT-related hypophosphatemia. Methods: In heart surgery patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) with regional citrate anticoagulation (RCA), we combined an 18 mmol/l citrate solution with a phosphate-containing (1.2 mmol/l) dialysate/replacement fluid evaluating the incidence of hypophosphatemia and the need for parenteral phosphorus supplementation. Results: In 75 patients on RCA-CVVHDF, the mean filter life was 53.9 ± 33.6 h. Regardless of baseline levels, phosphoremia was progressively corrected and maintained in a narrow normality range throughout RCA-CRRT days (after 72 h: 1.14 ± 0.25 mmol/l). Considering the whole CRRT period, 45 out of 975 (4.6%) serum phosphorus determinations met the criteria for mild (<0.81 mmol/l) or moderate (<0.61 mmol/l) hypophosphatemia; severe hypophosphatemia (<0.32 mmol/l) never occurred. After 72 h 88% of the patients were normophosphatemic, 9% hyperphosphatemic and 3% hypophosphatemic. Conclusions: RCA-CVVHDF with a phosphate-containing solution enabled the maintenance of phosphorus levels within normophosphatemic range in most of the patients, minimizing the occurrence of CRRT-related hypophosphatemia.
Tailoring dialysis prescriptions in critically ill patients with severe acute kidney injury (AKI) represents a significant challenge, requiring a balance between adequate solute clearance and the minimization of treatment-related complications. Recent evidence highlights the potential advantages of a low dialysis dose in limiting electrolyte disturbances, preserving essential nutrients, and reducing the need for pharmacologic interventions, while maintaining effective metabolic control. Regional citrate anticoagulation (RCA), widely considered as the first anticoagulation strategy for Continuous Kidney Replacement Therapy (CKRT), also contributes to dialysis buffer balance through the indirect generation of bicarbonate from citrate metabolism. In this regard, modulation of citrate metabolic load may allow the optimization of acid–base balance without increasing dialysis intensity. Therefore, RCA may represent a versatile tool to individualize CKRT prescriptions, enabling both effective metabolic management and lower dialysis doses, thereby enhancing patient safety and therapeutic efficiency in the intensive care setting.